focus -WSS

focus

author：entertainment 2025-09-29 12:30:18 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

explore

WSS

Gene editing the human germline: What are the risks?

Cholera vaccine supply gets boost as demand surges globally

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

5 to watch: Tech startups trying to solve health care's staffing crisis

Cholera vaccine supply gets boost as demand surges globally

Bird flu outbreak in cows is latest avian flu curveball

hotspot

focus

focus

Virginia high school admissions case could be legal follow

CVS Caremark has created a new ploy: the drug ‘rebate credit’

In age of alternative facts, a scholarly course on calling out crap

Cholera vaccine supply gets boost as demand surges globally

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cue Health's Covid

Virginia high school admissions case could be legal follow

Melinda French Gates resigns from Gates Foundation

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Q&A: Jennifer Adair on making gene therapy available globally

hotspot

Virtual Event: March of the Biosimilars

After traumatic brain injury, life support decisions can use more time

Orchard's therapy for neuron disease in children wins FDA approval

Getting Alzheimer's drug Leqembi to patients can be a challenge

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Positive childhood experiences can help future health

explore

focus

hotspot

hotspot